Patients reported any problems or faults with HumaPen Ergo ® at each study visit and any pens felt to have a potential fault were submitted to the HumaPen Ergo ® development team for testing.

At entry to the study 43 patients (61%) were using Novopen ® 3 to administer their insulin, 22 (31%) were using syringes, and five (7%) had used a combination of Novopen ® 3 and syringes.